Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low - What's Next?

Key Points

• Kailera Therapeutics shares hit a new 52-week low, falling to $11.84 and last trading at $11.99, down from the previous close of $12.83.
• Analyst sentiment is mixed: the consensus rating is “Moderate Buy” with a $42.75 target price, although recent coverage included “sell” ratings.
• The company reported a quarterly loss of $1.09 per share, missing expectations by $0.35, while several institutional investors—including Atlas Venture and Wellington Management—established new positions.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as $11.84 and last traded at $11.99, with a volume of 1050237 shares trading hands. The stock had previously closed at $12.83.

Wall Street Analyst Weigh In

KLRA has been the topic of a number of analyst reports. Wall Street Zen cut shares of Kailera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Weiss Ratings initiated coverage on Kailera Therapeutics in a report on Friday, August 14th. They set a "sell (d)" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kailera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Stock Performance

The company has a market cap of $1.55 billion and a price-to-earnings ratio of -0.00. The stock has a 50 day simple moving average of $16.87.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). As a group, research analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tidal Investments LLC purchased a new stake in Kailera Therapeutics during the second quarter valued at $309,000. Squarepoint Ops LLC bought a new stake in shares of Kailera Therapeutics in the 2nd quarter worth about $993,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics during the 2nd quarter valued at about $24,233,000. Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics in the 2nd quarter valued at about $113,923,000. Finally, Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the 2nd quarter valued at about $64,308,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.